Pearl River Capital’s NovoCure NVCR Stock Holding History

Pearl River Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,952	Closed	-$808K	–	528
2021 Q3	$808K	Buy	+6,952	New	+$1.05M	0.22%	150

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pearl River Capital's NVCR Position: Q4 2021 in Review

Pearl River Capital sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 6,952 shares — an estimated $808K sold.

Pearl River Capital first reported a position in NVCR in Q3 2021 and held it in 1 quarter. The position peaked at $808K in Q3 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

Pearl River Capital reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
Pearl River Capital sold 6,952 NovoCure shares in Q4 2021, an estimated $808K.
Pearl River Capital first reported a position in NovoCure in Q3 2021 and held it in 1 quarter.
Pearl River Capital's NovoCure position peaked at $808K in Q3 2021.
311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Pearl River Capital's 13F filing for Q4 2021, filed 11 Feb 2022.